Sangamo Biosciences: Promising Genomic Medicine Pipeline and Strategic Advancements Justify Buy Rating

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on SGMO stock, giving a Buy rating today.

Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Sangamo Biosciences’ promising developments in its genomic medicine pipeline. The company is entering a period rich with catalysts, particularly with the anticipated pivotal data readout from the Phase 2 STAAR trial for Fabry disease by the end of the second quarter of 2025. This event could significantly reduce risks ahead of the expected Biologics License Application filing in the first quarter of 2026, potentially leading to a first-in-class gene therapy approval and commercial launch in the second half of 2026.
Additionally, Sangamo’s advancements in its neurology programs, such as ST-503 for chronic neuropathic pain and ST-506 for prion disease, are on track for clinical development with promising preliminary data expected by the fourth quarter of 2026. The company’s STAC-BBB delivery platform has also secured high-value licensing agreements with major industry players, providing external validation and financial support. These strategic moves, coupled with recent financial maneuvers extending their operational runway, position Sangamo to unlock significant value, justifying the Buy rating.

In another report released today, Barclays also maintained a Buy rating on the stock with a $5.00 price target.